Janssen Pharmaceuticals, Inc. announced the FDA has approved the supplemental New Drug Application for NUCYNTA ER extended-release tables for the management of neuropathic pain associated with diabetic peripheral neuropathy. NUCYNTA ER is the first and only opioid approved by the FDA for this purpose. “Pain from DPN can be difficult to manage, leaving some patients and healthcare professionals looking for alternative treatments,” said Dr. Keith Candotti, Professor of Anesthesiology and Internal Medicine, University of Miami School of Medicine. READ MORE
Source: PRNewswire